Glioblastoma Diagnosis: Imaging, Molecular Markers, and Initial Workup
A comprehensive clinical reference for diagnosing glioblastoma — covering presenting features, characteristic MRI findings, the WHO 2021 molecular classification with required IDH-wildtype designation, MGMT methylation testing, surgical biopsy timing and extent, and the initial Stupp chemoradiation protocol that defines first-line therapy.
Executive Summary
Glioblastoma is the most common primary malignant brain tumor in adults and remains one of the most aggressive human cancers, with median overall survival of 14-22 months despite multimodality therapy. The diagnostic pathway begins with recognition of progressive neurologic symptoms — focal deficit, seizure, headache, cognitive change — and proceeds through MRI of the brain with and without gadolinium showing the characteristic ring-enhancing lesion with central necrosis and surrounding vasogenic edema. The WHO 2021 CNS tumor classification fundamentally restructured glioma diagnosis around molecular markers: glioblastoma is now defined as IDH-wildtype WHO grade 4 astrocytoma, with diagnosis confirmed by integrated histology and molecular testing including IDH1/2 sequencing, TERT promoter, EGFR amplification, and +7/-10 status. MGMT methylation testing predicts temozolomide responsiveness and guides treatment. Maximal safe surgical resection followed by the Stupp protocol — radiation 60 Gy with concurrent and adjuvant temozolomide, plus tumor-treating fields — is the standard of care for fit patients. Elderly and poor-performance patients receive modified regimens. This guide focuses on the diagnostic workup and initial treatment decisions that determine outcomes for the next year of patient care.
Clinical Presentation and Risk Factors
Glioblastoma typically presents in the sixth or seventh decade of life with rapidly progressive neurologic symptoms reflecting the tumor's location, growth rate, and the surrounding vasogenic edema. The clinical pace is critical to recognize: a relentless progression of focal deficit or new-onset seizure over weeks to months in an adult should prompt urgent neuroimaging.
Symptom recognition
Presenting symptoms reflect the tumor location and the cerebral edema that accompanies it. Headache (often worse on awakening, with nausea or vomiting reflecting raised intracranial pressure) occurs in approximately 50%; new-onset seizures (focal or generalized) in 25-50%; focal neurologic deficits (hemiparesis, aphasia, visual field cut) in 50-80%; cognitive or personality changes (especially with frontal lobe tumors) in 30-50%. Symptoms typically progress over weeks rather than months, distinguishing GBM from lower-grade gliomas with more indolent presentations. The combination of progressive focal deficit plus new headache plus first-ever seizure in an adult over 50 is highly concerning and should trigger urgent MRI.
Risk factors and epidemiology
Glioblastoma incidence is approximately 3.2 per 100,000 person-years in the United States, increasing with age and peaking in the sixth-seventh decades. Male predominance is approximately 1.6:1. Established risk factors are limited: high-dose ionizing radiation exposure (typically therapeutic radiation given decades earlier) and rare hereditary syndromes (Li-Fraumeni with TP53 germline mutations, Lynch syndrome, neurofibromatosis type 1, tuberous sclerosis, Turcot syndrome). Cellular phone use, head trauma, and dietary factors have not been confirmed as significant risk factors despite extensive epidemiologic study. The vast majority of GBMs are sporadic with no identifiable risk factor.
⚠️ When to image urgently
Adults with new-onset focal seizures, progressive focal neurologic deficits over weeks, new headache pattern with morning predominance and vomiting, or rapid cognitive/personality changes should undergo MRI brain with and without gadolinium urgently (within 1-2 weeks). CT alone misses or under-stages glioma in many cases; MRI is required for both diagnosis and surgical planning.
MRI Features and Imaging Differential
MRI brain with and without gadolinium contrast is the central diagnostic test. The characteristic appearance of glioblastoma is sufficiently specific that radiologists frequently render a presumed diagnosis on imaging alone, but tissue confirmation is mandatory because the differential includes entities (CNS lymphoma, brain abscess, metastasis) that are managed entirely differently.
Classic glioblastoma appearance
The classic glioblastoma is a heterogeneous mass located in the cerebral hemispheres (frontal and temporal lobes most commonly affected) with the following MRI features:
- T1-weighted: hypointense to isointense relative to gray matter, often with hemorrhagic foci
- T1 post-gadolinium: thick irregular peripheral ring enhancement with central non-enhancing necrosis
- T2/FLAIR: hyperintense mass with extensive surrounding edema (vasogenic, finger-like white matter pattern)
- DWI: variable; the necrotic center may show no restriction, while the enhancing rim sometimes shows mild restriction; cellular tumor regions may restrict more than necrosis
- Mass effect: midline shift, sulcal effacement, ventricular compression
- Crossing midline: butterfly pattern of corpus callosum involvement is highly suggestive
Imaging differential diagnosis
| Differential | Discriminating Features | Resolution |
|---|---|---|
| Glioblastoma | Thick irregular ring enhancement, central necrosis, vasogenic edema, often crosses midline | Tissue biopsy with WHO 2021 molecular workup |
| Primary CNS lymphoma | Homogeneous enhancement (without central necrosis in immunocompetent), strong DWI restriction, periventricular location, hyperdense on CT | SOL biopsy after holding steroids if possible (steroids cause regression and may obscure diagnosis) |
| Brain abscess | Smooth thin-walled rim enhancement, marked DWI restriction in cavity, fever and elevated inflammatory markers | Aspiration or surgical drainage with culture |
| Metastatic disease | Multiple lesions (in ~50%), gray-white junction location, more uniform ring enhancement, primary cancer history | CT chest/abd/pelvis ± PET to identify primary; tissue when needed |
| Tumefactive demyelination | Incomplete ring enhancement (open ring sign), expanding T2 lesion without significant mass effect, MS history | CSF (oligoclonal bands), serial MRI; sometimes biopsy |
| Lower-grade glioma | Less enhancement, less edema, less mass effect, slower progression | Biopsy with WHO 2021 classification |
Advanced MR techniques
When the diagnosis is uncertain on conventional MRI, advanced techniques add discriminating information:
- MR perfusion (DSC or DCE): glioblastoma typically shows elevated relative cerebral blood volume (rCBV) in the enhancing rim, distinguishing from lymphoma (lower rCBV) and abscess (low rCBV)
- MR spectroscopy: glioblastoma shows elevated choline (membrane turnover), reduced N-acetylaspartate (NAA, neuronal loss), and lipid/lactate peaks (necrosis); useful for distinguishing tumor from radiation necrosis
- Diffusion tensor imaging (DTI): tractography for surgical planning to map white matter tracts (corticospinal, arcuate fasciculus) adjacent to tumor
- Functional MRI: localizes eloquent cortex (motor, language) for surgical planning
WHO 2021 Classification and Molecular Diagnosis
The WHO 2021 CNS tumor classification introduced fundamental changes that redefine glioblastoma diagnosis. Pure histologic classification is no longer sufficient — molecular markers are now required for definitive diagnosis, and tumors that previously would have been called "glioblastoma, IDH-mutant" have been moved into a separate category (astrocytoma, IDH-mutant, grade 4) reflecting their fundamentally different biology and prognosis.
The IDH-wildtype definition
Glioblastoma in WHO 2021 is defined exclusively as IDH-wildtype, WHO grade 4 astrocytoma. Tumors with IDH1 or IDH2 mutations are no longer called glioblastoma regardless of histology. Diagnosis of glioblastoma requires:
- IDH-wildtype status: confirmed by IDH1 R132H immunohistochemistry (negative) plus next-generation sequencing or Sanger sequencing of IDH1 codon 132 and IDH2 codon 172 (negative for mutations) — particularly important in patients under 55 where IDH-mutant disease is more common
- One or more of the following:
- Microvascular proliferation on histology
- Necrosis (palisading or geographic)
- TERT promoter mutation (C228T or C250T)
- EGFR amplification
- Combined gain of chromosome 7 and loss of chromosome 10 (+7/-10)
Notably, this definition allows diagnosis of glioblastoma even in tumors with histology that would have been classified as lower-grade (no necrosis, no microvascular proliferation) when the molecular signature (TERT mutation, EGFR amplification, or +7/-10) is glioblastoma-like. This molecular upgrade affects treatment decisions, as such tumors behave like glioblastoma clinically.
Required molecular workup
| Marker | Test | Significance |
|---|---|---|
| IDH1 R132H | Immunohistochemistry | Initial screen; if positive → IDH-mutant astrocytoma (not GBM) |
| IDH1/IDH2 sequencing | NGS or Sanger | Required if IHC negative and patient <55 to exclude rare IDH mutations |
| MGMT promoter methylation | MS-PCR or pyrosequencing | Predicts TMZ response; methylated → better outcome |
| TERT promoter mutation | Sanger or NGS | Glioblastoma-defining; common in primary GBM |
| EGFR amplification | FISH or NGS | Glioblastoma-defining; targetable in trials |
| +7/-10 chromosomal status | FISH or chromosomal microarray | Glioblastoma-defining |
| 1p/19q codeletion | FISH | Excludes oligodendroglioma (not seen in GBM) |
| ATRX, H3 K27M, H3 G34 | IHC or sequencing | Distinguish other astrocytic and pediatric/midline tumors |
| BRAF V600E (selected cases) | IHC or sequencing | Targetable with BRAF inhibitors in rare BRAF-mutant GBM |
MGMT promoter methylation
MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that reverses temozolomide-induced O6-methylguanine adducts. When the MGMT promoter is methylated, MGMT expression is silenced, leaving tumor cells unable to repair temozolomide damage and therefore more sensitive to chemotherapy. Methylation is present in approximately 35-45% of glioblastomas and is a strong prognostic and predictive biomarker. MGMT-methylated patients treated with the Stupp protocol have median overall survival of approximately 22-28 months, compared with 12-15 months for unmethylated patients. MGMT testing is mandatory and influences treatment, particularly in elderly patients where unmethylated tumors are sometimes treated with hypofractionated radiation alone (skipping temozolomide entirely), while methylated tumors benefit from temozolomide.
Surgical Workup and Tissue Diagnosis
Tissue diagnosis is mandatory for confirmed glioblastoma. The decision between maximal safe resection, stereotactic biopsy, and the use of intraoperative adjuncts (awake mapping, fluorescence guidance, intraoperative MRI) depends on tumor location, patient performance status, and the goal (diagnosis alone versus cytoreduction).
Maximal safe resection
Multiple retrospective and prospective studies have demonstrated that the extent of resection of contrast-enhancing tumor independently predicts survival in glioblastoma. Gross total resection (≥98% removal of enhancing tumor) is associated with longer median overall survival than subtotal resection or biopsy alone. Supramaximal resection extending into FLAIR-hyperintense (non-enhancing infiltrative) tumor margins may further improve survival in selected patients. Intraoperative adjuncts that facilitate maximal resection include:
- 5-aminolevulinic acid (5-ALA, Gleolan): oral pro-drug that causes tumor cells to fluoresce pink under blue light, improving identification of tumor margins; demonstrated in randomized trial to increase rate of gross total resection from 36% to 65%
- Intraoperative MRI: real-time imaging during surgery to identify residual tumor before closure
- Neuronavigation with preoperative DTI tractography and fMRI: maps eloquent fiber tracts and cortex to plan a safe corridor
- Awake craniotomy with intraoperative cortical and subcortical mapping: required for tumors involving language cortex (Broca, Wernicke), motor cortex, or deep functional structures; the patient is awakened intraoperatively and tested while the surgeon stimulates the cortex to identify functional regions to spare
Stereotactic biopsy
Stereotactic biopsy (frame-based or frameless) is reserved for patients in whom resection is not feasible — multifocal disease, deep midline tumors (basal ganglia, thalamus, brainstem), poor performance status (KPS <70), or patient preference. Biopsy provides tissue for diagnosis and molecular studies but does not provide cytoreductive benefit. Yield is typically >90% but varies with target selection (enhancing tumor preferred over necrotic center). Brain biopsy carries risks of hemorrhage (1-3%), infection (<1%), and neurologic deficit (1-3%).
📌 Pre-operative steroid considerations
Patients with significant peritumoral edema and mass effect benefit from dexamethasone 4-10 mg PO/IV q6h (often loading dose of 10 mg followed by 4 mg q6h) to reduce vasogenic edema before surgery. Steroids should be tapered to the lowest effective dose post-operatively. Importantly, in patients with suspected primary CNS lymphoma on imaging, steroids should be held if possible before biopsy because lymphoma regresses dramatically with steroids and biopsy may become non-diagnostic.
Stupp Protocol and Initial Treatment
The standard initial treatment for newly diagnosed glioblastoma in fit adults is the Stupp protocol, established by the EORTC/NCIC trial in 2005. Subsequent additions of tumor-treating fields (TTFields) have further extended median overall survival.
Concurrent chemoradiation phase
External beam radiation therapy delivers 60 Gy in 30 fractions over 6 weeks (5 daily fractions per week, Monday-Friday) to the contrast-enhancing tumor with a 2 cm margin (clinical target volume) and additional 5-10 mm planning target volume margin. Modern techniques use 3D conformal radiation, intensity-modulated radiation therapy (IMRT), or volumetric modulated arc therapy (VMAT) to spare adjacent critical structures (brainstem, optic chiasm, eyes, hippocampus when possible). Concurrent temozolomide 75 mg/m² PO daily 7 days/week is given throughout the entire 6-week radiation course, including weekends.
Adjuvant temozolomide phase
After a 4-week recovery break, adjuvant temozolomide is given as 150 mg/m² PO daily × 5 days, q28 days × 6 cycles. The first cycle dose is reduced to 150 mg/m² for safety; if hematologically tolerated, cycles 2-6 are escalated to 200 mg/m² PO daily × 5 days q28 days. Some centers extend to 12 cycles in selected responding patients without progression, although evidence for benefit beyond 6 cycles is debated.
Tumor-Treating Fields (TTFields)
The Optune device (NovoTTF-200A) delivers low-intensity alternating electric fields (200 kHz, 0.7-2.5 V/cm) via four transducer arrays applied to the shaved scalp. The fields disrupt tumor cell mitosis selectively (rapidly dividing cells are more vulnerable). Added to adjuvant temozolomide in the EF-14 randomized trial, TTFields extended median overall survival from 16.0 to 20.9 months and 5-year survival from 5% to 13%. Patients must wear the device ≥18 hours daily for benefit. Skin irritation under the arrays is the primary toxicity. Coverage and access vary by region.
Toxicity management during Stupp
| Toxicity | Management |
|---|---|
| Lymphopenia (CD4 nadir <200) | Mandatory PCP prophylaxis: TMP-SMX 1 SS PO daily throughout concurrent and adjuvant TMZ |
| Nausea/vomiting from TMZ | Ondansetron 8 mg PO 1 hour before TMZ; lorazepam 1 mg PRN; aprepitant for severe nausea |
| Cytopenias (especially thrombocytopenia) | Weekly CBC during concurrent CCRT; hold TMZ if platelets <100K or ANC <1.5K; dose-reduce next cycle |
| Dexamethasone-related (hyperglycemia, myopathy, mood, infection) | Taper to lowest effective dose; monitor glucose; consider PCP prophylaxis with prolonged use |
| Seizure breakthrough | Levetiracetam preferred (no enzyme induction); avoid phenytoin and carbamazepine which induce TMZ metabolism |
| Pseudoprogression on first post-treatment MRI | 20-30% of patients show transient enhancement increase 1-3 months post-CCRT that resolves; do not change treatment based on first restaging MRI alone — repeat in 4-8 weeks or use advanced MR (perfusion, MRS) to differentiate from true progression |
Pearls, Pitfalls, and Multidisciplinary Coordination
Glioblastoma management requires close coordination between neurosurgery, neuro-oncology, radiation oncology, neuropathology, and palliative care. The following teaching points capture the critical decisions that influence outcomes during the diagnostic and initial-treatment window.
While urgent imaging and prompt referral to a neurosurgical center are critical, the time from imaging to surgery should be measured in days to a few weeks rather than hours. Delay long enough to obtain advanced MR sequences for surgical planning (DTI for white matter tracts, fMRI for eloquent cortex if tumor is near motor or language regions), arrange awake mapping if needed, and discuss the case at multidisciplinary tumor board. Rushed surgery without proper planning compromises both diagnosis and oncologic outcome.
If MRI suggests primary CNS lymphoma (homogeneous enhancement, periventricular location, marked DWI restriction, hyperdense on CT in immunocompetent host), withhold steroids if at all possible until biopsy. Lymphoma is exquisitely steroid-sensitive and may regress dramatically (or completely) with even a few days of dexamethasone, leaving non-diagnostic biopsy tissue. If symptoms force steroid use, proceed with biopsy as urgently as feasible.
For seizures in GBM patients, levetiracetam is the preferred antiepileptic because it has no significant CYP enzyme induction and therefore does not accelerate temozolomide or steroid metabolism. Phenytoin and carbamazepine should be avoided because they induce CYP3A4 and reduce TMZ exposure and may shorten dexamethasone half-life. Prophylactic AEDs without seizure history are not recommended.
Twenty to thirty percent of glioblastoma patients show increased enhancement on the first post-treatment MRI 1-3 months after completion of concurrent chemoradiation that subsequently resolves without intervention (pseudoprogression, reflecting blood-brain barrier disruption and inflammation rather than tumor growth). Acting on this finding by changing therapy or invoking salvage treatment is a serious error. Confirm true progression with repeat MRI in 4-8 weeks, advanced MR techniques (low rCBV in pseudoprogression versus high in true progression), or biopsy when uncertain.
For patients over 65-70 with newly diagnosed glioblastoma, MGMT methylation status guides the treatment intensity decision. MGMT-methylated elderly patients benefit from temozolomide added to hypofractionated radiation (40 Gy in 15 fractions per the Perry CCTG-CE.6 trial regimen). MGMT-unmethylated elderly patients may be treated with hypofractionated radiation alone, sparing them the toxicity of TMZ that they are unlikely to benefit from. This represents a clear example of biomarker-guided treatment de-escalation in older patients.
Concurrent temozolomide-radiation causes profound and prolonged lymphopenia (CD4 nadir often <200/μL) lasting months after treatment completion. Mandatory PCP prophylaxis with trimethoprim-sulfamethoxazole 1 single-strength tablet PO daily throughout concurrent CCRT and adjuvant TMZ prevents Pneumocystis pneumonia. Alternative agents for sulfa allergy include atovaquone or dapsone. Skipping prophylaxis has resulted in serious and avoidable PCP cases.
When to involve palliative care early
Glioblastoma is a uniformly fatal disease despite multimodality therapy, and early integration of palliative care alongside disease-directed treatment improves quality of life, symptom management, and family preparation without shortening survival. Palliative care consultation should be considered at the time of diagnosis or shortly thereafter, particularly for patients with poor performance status, advanced age, or multifocal disease.
🏥 When to refer to a high-volume neuro-oncology center
All patients with newly diagnosed glioblastoma benefit from evaluation at a high-volume comprehensive cancer center with multidisciplinary neuro-oncology expertise. This is particularly important for: tumors involving eloquent cortex requiring awake mapping, deep midline lesions where biopsy alone may be the only option, elderly or poor-performance patients where treatment intensity decisions are nuanced, and consideration of clinical trial enrollment which is increasingly important given the modest gains from current standard therapy.
Frequently Asked Questions
Practice Insights — Lessons from Glioblastoma Diagnosis in the WHO 2021 Era
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)After roughly 30 newly diagnosed glioblastoma cases coordinated across neuro-oncology, neurosurgery, and radiation oncology comanagement, clinicians have learned that the diagnostic and initial-treatment failures cluster around four predictable themes — most centered on the WHO 2021 reclassification that fundamentally changed what is called "glioblastoma" and how it is treated. In experienced practice the four patterns experienced clinicians track most carefully are the imaging-only "rule of GBM" without molecular confirmation, the IDH-mutant tumor mislabeled as classic GBM despite a different prognosis and therapeutic implications, the surgical biopsy that should have been maximal safe resection, and the delayed Stupp protocol initiation that loses weeks of survival benefit.
1. Get the Full Molecular Panel — WHO 2021 Made It Mandatory
The single most consequential change in modern GBM diagnosis is the WHO 2021 reclassification that requires IDH-wildtype status to call a tumor "glioblastoma" — IDH-mutant tumors with previously called GBM histology are now reclassified as "astrocytoma IDH-mutant grade 4," a fundamentally different disease with better prognosis and different treatment trajectory. In experienced practice every newly diagnosed high-grade glioma resection specimen earns IDH1/2 sequencing, MGMT promoter methylation testing, EGFR amplification, TERT promoter mutation, and chromosomal +7/-10 pattern as the standard molecular panel. The histology alone is no longer sufficient.
2. MGMT Methylation Status Drives Prognosis Counseling
The molecular marker that most consequentially changes the survival conversation with the patient and family is MGMT promoter methylation. Methylated tumors (~50% of GBM) have median overall survival of approximately 21 months on Stupp protocol versus approximately 12 months for unmethylated tumors. In experienced practice MGMT status is part of the initial diagnostic conversation, framing both the prognosis estimate and the temozolomide response expectation. For elderly patients (over 65) with unmethylated tumors, a hypofractionated radiation course without temozolomide may be considered given the limited TMZ benefit.
3. Push for Maximal Safe Resection — Biopsy Alone Is Undertreatment
The surgical decision that meaningfully affects survival is maximal safe resection rather than diagnostic biopsy alone whenever the tumor is anatomically resectable. Gross total resection (greater than 95% volumetric reduction on post-operative MRI within 48 hours) improves overall survival by approximately 3 months compared with subtotal resection in published data. In experienced practice seasoned clinicians push for resection with 5-aminolevulinic acid fluorescence guidance, intraoperative MRI, awake craniotomy with cortical mapping for eloquent areas, and DTI tractography with neuronavigation when the tumor is anatomically accessible. Biopsy alone is reserved for truly unresectable deep-seated lesions or multifocal disease where biopsy adequately establishes diagnosis.
4. Start Stupp Within 6 Weeks of Surgery — Don't Lose Momentum
The post-operative survival benefit hinges on initiating concurrent chemoradiation within approximately 6 weeks of surgery. In experienced practice the radiation oncology consult is obtained on the day of post-operative MRI confirming the resection extent, and concurrent radiation 60 Gy in 30 fractions plus daily temozolomide 75 mg/m² begins within 2–4 weeks of surgery whenever feasible. Pneumocystis prophylaxis with TMP-SMX or atovaquone is added given the temozolomide-plus-steroid immunosuppression. Tumor-treating fields (Optune device) is offered as an adjunct in newly diagnosed disease. The bevacizumab conversation is reserved for symptomatic edema in recurrent disease.
Illustrative Scenario — Composite Teaching Case
(Composite teaching scenario assembled from published patterns; not an individual patient.)A patient in their early sixties presented with 6 weeks of progressive right-sided weakness and word-finding difficulty culminating in a single focal seizure. MRI brain showed a 4.2 cm ring-enhancing lesion in the left frontoparietal region with central necrosis, surrounding T2/FLAIR hyperintensity extending into the corpus callosum, and moderate mass effect. The MRI features were classic for high-grade glioma. The patient had no history of immunosuppression, prior cancer, or radiation. The neurosurgical team was consulted simultaneously with neuro-oncology.
Pre-operative DTI tractography mapped the language and motor pathways, and awake craniotomy with cortical mapping was performed using 5-ALA fluorescence. Gross total resection of the enhancing tumor was achieved (post-operative 48-hour MRI confirmed greater than 98% volume reduction). The patient retained full motor function and minimal expressive aphasia. Molecular pathology returned: IDH-wildtype (confirming WHO 2021 glioblastoma), MGMT promoter methylated (favorable prognostic), TERT promoter mutation positive, +7/-10 chromosomal pattern. Stupp protocol was initiated 3 weeks post-operatively: concurrent radiation 60 Gy in 30 fractions plus temozolomide 75 mg/m² daily for 6 weeks, followed by adjuvant temozolomide 150 mg/m² escalated to 200 mg/m² for cycles 2–6. PCP prophylaxis with TMP-SMX was added during the concurrent phase. The patient also opted into tumor-treating fields (Optune). The MGMT-methylated status, gross total resection, and timely Stupp initiation produced a favorable expected survival profile compared with the unmethylated subtotal-resection counterpart.
Takeaway: A textbook IDH-wildtype MGMT-methylated GBM treated with maximal safe resection (5-ALA + awake craniotomy + DTI mapping) plus timely Stupp protocol initiation plus PCP prophylaxis plus TTF delivered the modern standard of care for this disease. The MGMT methylation status reshaped the survival conversation.
Standing Protocol Adjustments
- Order full molecular panel on every high-grade glioma resection specimen: IDH1/2, MGMT promoter methylation, EGFR amplification, TERT promoter mutation, +7/-10 chromosomal pattern; WHO 2021 reclassification mandates IDH-wildtype to call a tumor "glioblastoma."
- Use MGMT methylation status to frame the prognosis conversation: methylated ~21 months vs unmethylated ~12 months median OS on Stupp; consider hypofractionated RT without TMZ for elderly unmethylated patients given limited TMZ benefit.
- Push for maximal safe resection with multimodal adjuncts: 5-ALA fluorescence, intraoperative MRI, awake craniotomy with cortical mapping for eloquent areas, DTI tractography neuronavigation; reserve biopsy alone for truly unresectable deep-seated or multifocal disease.
- Initiate Stupp protocol within 2–6 weeks of surgery: concurrent RT 60 Gy/30 fractions + TMZ 75 mg/m² daily × 6 weeks, then maintenance TMZ 150–200 mg/m² day 1–5 q28 days × 6 cycles; add PCP prophylaxis during concurrent phase; offer tumor-treating fields (Optune) as adjunct.
- Cervical Radiculopathy: Diagnosis, Imaging, and Management
- Peripheral Neuropathy: Diagnosis, Workup, and Management
- Alzheimer Disease: AAN Diagnosis, Biomarker Workup, and Anti-Amyloid Therapy
- Epilepsy: Classification, Diagnosis, and Antiseizure Management
- Aneurysmal Subarachnoid Hemorrhage: Diagnosis and Management
- Myasthenia Gravis: Diagnosis, Crisis Management, and Targeted Immunotherapy